PharmaCyte BiotechPMCB
About: PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Employees: 2
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.46% less ownership
Funds ownership: 12.22% [Q2] → 10.76% (-1.46%) [Q3]
7% less funds holding
Funds holding: 28 [Q2] → 26 (-2) [Q3]
22% less capital invested
Capital invested by funds: $2.02M [Q2] → $1.58M (-$445K) [Q3]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
70% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for PMCB.
Financial journalist opinion
